MX2017007390A - Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. - Google Patents
Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales.Info
- Publication number
- MX2017007390A MX2017007390A MX2017007390A MX2017007390A MX2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A MX 2017007390 A MX2017007390 A MX 2017007390A
- Authority
- MX
- Mexico
- Prior art keywords
- neoplasms
- central nervous
- immune checkpoint
- checkpoint inhibitors
- nervous systems
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title 1
- 208000032612 Glial tumor Diseases 0.000 abstract 2
- 206010018338 Glioma Diseases 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 abstract 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 1
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000005911 anti-cytotoxic effect Effects 0.000 abstract 1
- 101710135378 pH 6 antigen Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462092783P | 2014-12-16 | 2014-12-16 | |
| US201562261130P | 2015-11-30 | 2015-11-30 | |
| PCT/US2015/066177 WO2016100561A2 (en) | 2014-12-16 | 2015-12-16 | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017007390A true MX2017007390A (es) | 2017-11-06 |
Family
ID=56127849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017007390A MX2017007390A (es) | 2014-12-16 | 2015-12-16 | Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180133313A1 (enExample) |
| EP (1) | EP3233123A4 (enExample) |
| JP (2) | JP2018500332A (enExample) |
| CN (1) | CN106999590A (enExample) |
| BR (1) | BR112017010101A2 (enExample) |
| CA (1) | CA2969338A1 (enExample) |
| MX (1) | MX2017007390A (enExample) |
| RU (1) | RU2726996C1 (enExample) |
| WO (1) | WO2016100561A2 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3081576T1 (sl) | 2013-12-12 | 2019-12-31 | Shanghai Hengrui Pharmaceutical Co., Ltd., | Protitelo PD-1, njegov antigen-vezavni fragment in njegova medicinska uporaba |
| CN105296433B (zh) | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| HRP20201031T1 (hr) | 2015-05-29 | 2020-10-16 | Agenus Inc. | Anti-ctla-4 protutijela i postupci njihove upotrebe |
| PL3334763T3 (pl) | 2015-08-11 | 2024-12-02 | WuXi Biologics Ireland Limited | Nowe przeciwciała anty-pd-1 |
| MA48579A (fr) | 2015-09-01 | 2020-03-18 | Agenus Inc | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci |
| WO2017176925A1 (en) | 2016-04-05 | 2017-10-12 | Bristol-Myers Squibb Company | Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment |
| EP3497129A1 (en) * | 2016-08-08 | 2019-06-19 | H. Hoffnabb-La Roche Ag | Therapeutic and diagnostic methods for cancer |
| WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
| GB201618291D0 (en) * | 2016-10-28 | 2016-12-14 | Bergen Teknologioverf�Ring As | Novel immunotherapeutic treatments for tumours |
| WO2018106729A1 (en) * | 2016-12-05 | 2018-06-14 | G1 Therapeutics, Inc. | Preservation of immune response during chemotherapy regimens |
| AU2017373944B2 (en) | 2016-12-07 | 2022-02-03 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| AU2017373945B2 (en) | 2016-12-07 | 2025-01-23 | Agenus Inc. | Antibodies and methods of use thereof |
| DE102017119868B4 (de) * | 2017-07-12 | 2021-05-27 | Bruker Daltonik Gmbh | Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie |
| JP7159007B2 (ja) * | 2017-11-01 | 2022-10-24 | 小野薬品工業株式会社 | 脳腫瘍の治療のための医薬 |
| CN111971306A (zh) * | 2018-03-30 | 2020-11-20 | 百时美施贵宝公司 | 治疗肿瘤的方法 |
| SG11202011651SA (en) * | 2018-05-31 | 2020-12-30 | Ono Pharmaceutical Co | Biomarkers for determining the effectiveness of immune checkpoint inhibitors |
| WO2020191240A1 (en) * | 2019-03-19 | 2020-09-24 | Chemocentryx, Inc. | Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1 and/or pd-l1 inhibitor |
| CA3152250A1 (en) * | 2019-09-10 | 2021-03-18 | Novocure Gmbh | A method of reducing viability of cancer cells by applying alternating electric fields and administering checkpoint inhibitors to the cancer cells |
| WO2021127254A1 (en) * | 2019-12-19 | 2021-06-24 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| CA3162969A1 (en) * | 2019-12-27 | 2021-07-01 | Kunihiko Kobayashi | Cancer treatment method and medicine |
| WO2021231405A1 (en) * | 2020-05-12 | 2021-11-18 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| US20230365690A1 (en) * | 2020-08-07 | 2023-11-16 | Northwestern University | Methods of treating malignant glioblastoma |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5798919B2 (ja) * | 2008-08-25 | 2015-10-21 | アンプリミューン、インコーポレーテッドＡｍｐｌｉｍｍｕｎｅ， Ｉｎｃ． | Ｐｄ−１アンタゴニストの組成物および使用方法 |
| EP3133086B1 (en) * | 2008-09-26 | 2018-08-01 | Dana-Farber Cancer Institute, Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
| RU2402360C1 (ru) * | 2009-07-08 | 2010-10-27 | Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) | Способ лечения злокачественной глиомы головного мозга |
| CN102178676B (zh) * | 2011-04-29 | 2012-07-25 | 山东大学 | 一种治疗脑胶质瘤的药物组合物 |
| EP2723381A4 (en) * | 2011-06-21 | 2015-03-18 | Univ Johns Hopkins | FOCUSED RADIATION FOR THE REINFORCEMENT OF IMMUNE TREATMENTS AGAINST NEOPLASMS |
| WO2013173223A1 (en) * | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US9890215B2 (en) * | 2012-06-22 | 2018-02-13 | King's College London | Vista modulators for diagnosis and treatment of cancer |
| US10392442B2 (en) * | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
-
2015
- 2015-12-16 US US15/536,785 patent/US20180133313A1/en not_active Abandoned
- 2015-12-16 CA CA2969338A patent/CA2969338A1/en not_active Abandoned
- 2015-12-16 BR BR112017010101A patent/BR112017010101A2/pt not_active Application Discontinuation
- 2015-12-16 EP EP15871017.8A patent/EP3233123A4/en active Pending
- 2015-12-16 MX MX2017007390A patent/MX2017007390A/es unknown
- 2015-12-16 JP JP2017532140A patent/JP2018500332A/ja active Pending
- 2015-12-16 CN CN201580069022.6A patent/CN106999590A/zh active Pending
- 2015-12-16 RU RU2017125052A patent/RU2726996C1/ru active
- 2015-12-16 WO PCT/US2015/066177 patent/WO2016100561A2/en not_active Ceased
-
2020
- 2020-07-20 US US16/933,547 patent/US20210000953A1/en not_active Abandoned
-
2021
- 2021-08-12 JP JP2021131637A patent/JP2021181482A/ja active Pending
-
2023
- 2023-12-06 US US18/531,312 patent/US20240238416A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| RU2726996C1 (ru) | 2020-07-17 |
| US20180133313A1 (en) | 2018-05-17 |
| BR112017010101A2 (pt) | 2018-01-02 |
| JP2018500332A (ja) | 2018-01-11 |
| WO2016100561A2 (en) | 2016-06-23 |
| EP3233123A4 (en) | 2018-05-09 |
| US20240238416A1 (en) | 2024-07-18 |
| JP2021181482A (ja) | 2021-11-25 |
| WO2016100561A3 (en) | 2016-08-18 |
| US20210000953A1 (en) | 2021-01-07 |
| EP3233123A2 (en) | 2017-10-25 |
| CA2969338A1 (en) | 2016-06-23 |
| CN106999590A (zh) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017007390A (es) | Uso de inhibidores de punto de control inmunitario en neoplasmas de sistemas nerviosos centrales. | |
| MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
| NZ728688A (en) | Anti-pd-1 antibodies | |
| MX2020001272A (es) | Anticuerpos dirigidos contra interleucina-33 (il-33). | |
| MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
| MX2022001757A (es) | Inhibidores de muerte programada 1 (pd-19)/ligando de muerte programada 1 (pd-l1) para el tratamiento de cancer. | |
| PT3858859T (pt) | Método de tratamento de cancro utilizando um inibidor do ponto de controlo imunológico; anticorpo que se liga ao recetor-1 de morte programada (pd-1) ou ligando-1 de morte programada (pd-l1) | |
| PH12018500711A1 (en) | Anti-pd1 antibodies and methods of use | |
| PH12020500075A1 (en) | Checkpoint inhibitor bispecific antibodies | |
| EP3572430A3 (en) | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent | |
| ZA201801852B (en) | Anti¿pd¿1 antibodies and compositions | |
| PH12016501894B1 (en) | Anti-ox40 antibodies and methods of use | |
| MX2018014435A (es) | Inhibidores de muerte programada 1 (pd-1) ligando de muerte programada (pd-l1) para el tratamiento de cancer. | |
| EA201790926A1 (ru) | Комбинированное лечение злокачественного новообразования | |
| MX2017007491A (es) | Anticuerpos del receptor de la barrera hematoencefálica y métodos para su uso. | |
| MX2017000857A (es) | Combinación de un antagonista de la proteina de muerte programada (pd-1) y una vacuna basada en listeria para tratar el cáncer de próstata. | |
| EA201691376A1 (ru) | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака | |
| NZ728674A (en) | Signalling system | |
| NZ744854A (en) | Compositions containing tucaresol or its analogs | |
| MX2015012428A (es) | Tratamiento contra enfermedades mediadas th2 por inhibicion de bromodominios. | |
| CO2017012988A2 (es) | Agentes, usos y métodos para el tratamiento | |
| IL250137A0 (en) | Method for inhibiting intracellular activated ras using intact immunoglobulin-type antibody having cytosol-penetrating ability and use thereof | |
| MX2023006786A (es) | Anticuerpos inmunomoduladores biespecificos que se fijan a receptores coestimuladores y de puntos de control. | |
| MX2019005089A (es) | Anticuerpos anti cumulo de diferenciacion 40 (cd40) en combinacion y metodos de uso. | |
| MX2017007097A (es) | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). |